MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-13-2026
OptimizeRx Corporation Income Statement 2011-2026 | OPRX
Annual Income Statement OptimizeRx Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
229 M | 214 M | 177 M | 237 M | 774 M | 669 M | 151 M | 119 M | 41.5 M | 23.8 M | 26.5 M | 23.7 M | 26.9 M | 14.9 M | 11.1 M | - |
Shares |
18.6 M | 18.3 M | 17.1 M | 17.8 M | 17.2 M | 14.8 M | 13.4 M | 10.8 M | 9.82 M | 9.9 M | 8.19 M | 7.46 M | 4.8 M | 4.74 M | 4.64 M | - |
Historical Prices |
12.4 | 11.7 | 10.3 | 13.3 | 44.9 | 45.1 | 11.1 | 11.2 | 4.11 | 2.31 | 3.24 | 3.18 | 5.61 | 3.15 | 2.4 | 5.85 |
Net Income |
5.13 M | -20.1 M | -17.6 M | -11.4 M | 378 K | -2.21 M | -3.14 M | 226 K | -2.1 M | -1.54 M | -595 K | -1.03 M | 216 K | -364 K | -2.12 M | -2.01 M |
Revenue |
109 M | 92.1 M | 71.5 M | 62.5 M | 61.3 M | 43.3 M | 24.6 M | 21.2 M | 12.1 M | 7.75 M | 7.22 M | 6.5 M | 4.96 M | 2.05 M | 1.11 M | 71.1 K |
Cost of Revenue |
35.8 M | 32.7 M | 28.6 M | 23.5 M | 25.7 M | 19.2 M | 9.16 M | 9 M | - | - | - | - | - | - | - | - |
Gross Profit |
73.6 M | 59.4 M | 42.9 M | 39 M | 35.6 M | 24.1 M | 15.4 M | 12.2 M | 5.95 M | 4.34 M | 3.6 M | 3.28 M | 3.19 M | 2.05 M | 1.11 M | - |
Operating Income |
11.7 M | -13.7 M | -26.4 M | -12.3 M | 361 K | -2.14 M | -3.69 M | 180 K | -2.13 M | -1.58 M | -597 K | -1.03 M | -268 K | -455 K | -1.45 M | -1.85 M |
Interest Expense |
- | - | 1.45 M | 852 K | 17 K | -71.8 K | -347 K | 46.2 K | - | - | - | - | - | 100 | -959 K | -107 K |
EBITDA |
16 M | -9.38 M | -24 M | -10.3 M | 2.33 M | -59.4 K | -1.61 M | 1.1 M | -1.81 M | -1.3 M | -263 K | -362 K | 410 K | -177 K | -1.31 M | -1.79 M |
Operating Expenses |
61.9 M | 73.1 M | 69.3 M | 51.3 M | 35.3 M | 26.2 M | 18.3 M | 11.4 M | 8.08 M | 5.87 M | 4.2 M | 3.91 M | 2.97 M | 2.41 M | 2.57 M | 1.92 M |
General and Administrative Expenses |
50.2 M | 49.8 M | 44.3 M | 744 K | 27.7 M | 21 M | 13.5 M | 9.99 M | 6.54 M | 4.94 M | 3.27 M | 3.37 M | 2.73 M | 2.17 M | 2.02 M | - |
All numbers in USD currency
Quarterly Income Statement OptimizeRx Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
18.8 M | 18.6 M | 18.5 M | 18.5 M | 18.5 M | 18.3 M | 18.3 M | 18.2 M | 18.2 M | 16.6 M | 17 M | 17.1 M | 18.3 M | 18 M | 18.1 M | 17.9 M | 17.9 M | 17.6 M | 17.3 M | 16.1 M | 15.2 M | 14.9 M | 14.7 M | 14.6 M | 14.6 M | 14.1 M | 12.7 M | 12.1 M | 12 M | 11.8 M | 11 M | 9.79 M | 9.77 M | 9.75 M | 9.86 M | 29.7 M | 29.7 M | 29.4 M | 29.1 M | 29 M | 29 M | 23.3 M | 22.9 M | 22.9 M | 22.9 M | 23.4 M | 23.2 M | 16.7 M | 14.8 M | 14.2 M | 33.6 M | 14.2 M | - | 14.2 M | 14.2 M | - | - | - | - | - |
Net Income |
-495 K | 779 K | 1.53 M | -2.2 M | - | -9.12 M | -4.01 M | -6.9 M | - | -2.86 M | -4.16 M | -6.4 M | - | -3.47 M | -3.88 M | -3.76 M | - | 39.9 K | 352 K | -637 K | - | -283 K | -1.08 M | -2.2 M | - | -1.57 M | 407 K | 6.53 K | - | 245 K | 281 K | -189 K | - | -623 K | -362 K | -883 K | - | -243 K | -592 K | -352 K | - | 87.9 K | -157 K | -111 K | - | -295 K | -199 K | -762 K | - | -412 K | -248 K | -224 K | - | -483 K | -377 K | -301 K | - | -2.03 M | -433 K | -380 K |
Revenue |
19.8 M | 26.1 M | 29.2 M | 21.9 M | - | 21.3 M | 18.8 M | 19.7 M | - | 16.3 M | 13.8 M | 13 M | - | 15.1 M | 14 M | 13.7 M | - | 16.1 M | 13.6 M | 11.2 M | - | 10.5 M | 8.78 M | 7.58 M | - | 5 M | 7.01 M | 5.21 M | - | 5.42 M | 5.1 M | 2.78 M | - | 3.1 M | 2.87 M | 1.4 M | - | 1.79 M | 1.91 M | 1.76 M | - | 2.01 M | 1.71 M | 1.49 M | - | 1.82 M | 1.43 M | 1.29 M | - | 1.37 M | 1.1 M | 669 K | - | 77 | 146 | 185 | - | 206 | 395 | 440 |
Cost of Revenue |
4.91 M | 8.55 M | 10.6 M | 8.58 M | - | 7.86 M | 7.11 M | 7.49 M | - | 6.53 M | 5.99 M | 5.57 M | - | 5.66 M | 4.99 M | 5.63 M | - | 7.05 M | 5.58 M | 5.1 M | - | 4.5 M | 3.64 M | 3.24 M | - | 1.98 M | 2.69 M | 1.58 M | - | 2.27 M | 2.24 M | 2.01 M | - | - | - | 1.38 M | - | - | - | 893 K | - | - | - | - | - | 859 K | - | - | - | 529 K | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | 17.5 M | 18.6 M | 13.3 M | - | 13.4 M | 11.7 M | 12.2 M | - | 9.8 M | 7.82 M | 7.43 M | - | 9.42 M | 8.99 M | 8.1 M | - | 9.08 M | 8.04 M | 6.12 M | - | 6.01 M | 5.14 M | 4.34 M | - | 3.02 M | 4.32 M | 3.63 M | - | 3.15 M | 2.86 M | 2.1 M | - | 1.4 M | 1.26 M | 770 K | - | 1.06 M | 990 K | 867 K | - | 963 K | 823 K | 731 K | - | 861 K | 697 K | 728 K | - | 844 K | 1.04 M | 653 K | - | - | - | - | - | - | - | - |
Operating Income |
396 K | 2.05 M | 3.19 M | -2.11 M | - | -8.56 M | -3.75 M | -5.03 M | - | -3.55 M | -4.85 M | -7.06 M | - | -3.76 M | -3.91 M | -3.76 M | - | 38.2 K | 340 K | -638 K | - | -177 K | -1.06 M | -2.26 M | - | -1.99 M | 480 K | 132 K | - | 223 K | 274 K | -191 K | - | -630 K | -371 K | -890 K | - | -249 K | -603 K | -362 K | - | 87.6 K | -158 K | -111 K | - | -295 K | -200 K | -762 K | - | -142 K | 354 K | 99.8 K | - | -106 K | -76.2 K | -301 K | - | 13.5 M | -420 K | -240 K |
Interest Expense |
- | - | - | - | - | - | - | 1.55 M | - | 688 K | 720 K | 665 K | - | 290 K | 23.8 K | 3 | - | 1.7 K | 12 K | 931 | - | -106 K | -21.7 K | 55.3 K | - | 416 K | -73.4 K | -126 K | - | - | - | - | - | - | - | - | - | 163 | 163 | 163 | - | - | - | - | - | - | - | - | - | - | - | - | - | -100 | - | - | - | -679 K | -140 K | -140 K |
EBITDA |
1.46 M | 3.13 M | 4.26 M | -1.02 M | - | -7.47 M | -2.68 M | -3.96 M | - | -3.09 M | -4.38 M | -6.6 M | - | -3.24 M | -3.33 M | -3.29 M | - | 1.62 M | 1.39 M | -638 K | - | -177 K | -1.06 M | -1.74 M | - | -1.24 M | 906 K | 322 K | - | 387 K | 383 K | -137 K | - | -417 K | -229 K | -819 K | - | -95.2 K | -501 K | -312 K | - | 330 K | 1.81 K | -31.8 K | - | -112 K | -84 K | -703 K | - | -93.4 K | 402 K | 148 K | - | -59.4 K | -28.9 K | -255 K | - | 13.5 M | -390 K | -210 K |
Operating Expenses |
- | 15.5 M | 15.4 M | 15.5 M | - | 22 M | 15.5 M | 17.2 M | - | 13.4 M | 12.7 M | 14.5 M | - | 13.2 M | 12.9 M | 11.9 M | - | 9.04 M | 7.7 M | 6.76 M | - | 6.19 M | 6.2 M | 6.6 M | - | 5.01 M | 3.84 M | 3.49 M | - | 2.92 M | 2.59 M | 2.3 M | - | 2.03 M | 1.63 M | 1.66 M | - | 1.31 M | 1.59 M | 1.23 M | - | 875 K | 981 K | 843 K | - | 1.16 M | 897 K | 1.49 M | - | 1.08 M | 750 K | 553 K | - | 559 K | 592 K | 630 K | - | 601 K | 621 K | 634 K |
General and Administrative Expenses |
3.51 M | 14.4 M | 14.4 M | 14.4 M | - | 13.4 M | 14.4 M | 16.2 M | - | 12.9 M | 12.2 M | 14 M | - | 12.7 M | 12.3 M | 11.4 M | - | 3.41 M | 2.9 M | 2.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 89.3 K | - | 94.8 K | 56.5 K | 219 K | - | 63.2 K | 57.1 K | 77 K | - | 133 K | 101 K | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company OptimizeRx Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B |  USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Evolent Health
EVH
|
$ 3.89 | -1.52 % | $ 444 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
HealthEquity
HQY
|
$ 87.73 | -0.43 % | $ 7.56 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 2.79 | 5.09 % | $ 994 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
10x Genomics
TXG
|
$ 24.66 | 4.14 % | $ 3.08 B | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.25 | -2.71 % | $ 87.4 M | USA |
 |
Schrödinger
SDGR
|
$ 13.37 | 0.53 % | $ 982 M | USA |
 |
Phreesia
PHR
|
$ 8.89 | -0.34 % | $ 531 M | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Teladoc Health
TDOC
|
$ 6.67 | 1.45 % | $ 1.18 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |
 |
American Well Corporation
AMWL
|
$ 8.21 | 3.14 % | $ 132 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
HealthStream
HSTM
|
$ 23.99 | 0.76 % | $ 720 M | USA |
 |
Omnicell
OMCL
|
$ 44.27 | -0.32 % | $ 2.03 B | USA |
 |
Progyny
PGNY
|
$ 25.28 | 1.61 % | $ 2.15 B | USA |
 |
So-Young International
SY
|
$ 2.03 | -9.19 % | $ 158 M |  China |
 |
Veeva Systems
VEEV
|
$ 158.9 | -0.79 % | $ 26 B | USA |
 |
Zhongchao
ZCMD
|
$ 1.43 | - | $ 4.89 M | China |